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Summary This study aimed to investigate whether immunohistochemical staining for nm23-H1 protein in the
primary tumour is correlated with tumour stage, tumour differentiation, DNA ploidy, cell proliferative index,
p53 status and patient survival time in colorectal cancer. Full-cross colorectal cancer biopsies were collected
from 202 consecutive surgical specimens between 1987 and 1990. Immunohistochemical expression of nm23-H1
protein was investigated in cryosections, using a monoclonal anti-nm23-Hl antibody (clone NM 301). The
staining pattern was classified as follows: strong homogeneous intensity, moderate homogeneous intensity,
moderate focal intensity, or as negative. Immunohistochemical expression of p53 was investigated using a
monoclonal anti-p53 antibody (DO-7). The DNA ploidy and cell proliferative index were determined by flow
cytometry. Possible correlation between nm23-HI staining patterns and the other studied tumour
characteristics was explored at the end of 1994. Median survival time of living patients was 66 months,
range 50-93 months. No correlation was found between various nm23-HI staining patterns and tumour stage,
cell proliferative index or p53 status. Nm23-H1-negative tumours and tumours with moderate focal staining
intensity were less differentiated than tumours with strong homogeneous or moderate homogeneous staining
intensity (P<0.05). Of the nm23-H1-negative tumours, a significantly higher number was near-diploid rather
than aneuploid, as compared with those expressing positive nm23-H1 (P<0.05). The number of dead patients
in Dukes' stages B and C did not correlate signficantly with the nm23-H1 staining pattern. The nm23-Hl
staining pattern alone, or combined with either of the other explored tumour characteristics, did not correlate
with patient survival time. Immunohistochemical studies of the nm23-HI protein expression are ofminor value
in the staging and prognostic prediction of colorectal cancer.
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The complex processes of tumour progression include both
positive and negative regulatory elements, such as activation of
oncogenes and inactivation oftumour-suppressor genes (Liotta
et al., 1991). The adenoma-carcinoma sequence in colorectal
cancer is a well-known cascade of multistep genetic events
including various mutations, some of which have been
characterised (Cawkwell etal., 1994; Fearon, 1994). Accumula-
tion ofthese and other unknown genetic changes is considered
to be necessary for tumorigenesis, but none of the known
changes can foretell metastatic potential (Fearon, 1994).
It was not long ago that the new human potential
metastasis-suppressor gene family, 'non-metastatic' nm23,
was identified (Steeg et al., 1988). nm23-H1 has been
mapped to human chromosome locus 17q21.3-22, and the
gene encodes a Mr 17 000 protein of unknown function
(Backer et al., 1993; Leone et al., 1991). Potential roles for
the nm23 protein have been suggested, such as in the
formation of a basement membrane, in tumour differentia-
tion and cell proliferation (Caligo et al., 1995; Howlett et al.,
1994; Lombardi et al., 1995).
A down-regulated expression of nm23-H 1, on either
mRNA and/or protein level, has been reported in various
human cancers (some with highly metastatic activities), such
as malignant melanoma (Florenes et al., 1992; Xerri et al.,
1994), squamous cell cancer of the lung (Huwer et al., 1994),
hepatocellular cancer (lizuka et al., 1995), ovarian cancer
(Mandai et al., 1994) and gastric cancer (Nakayama et al.,
1993). Similar findings have been reported for breast cancer
(Bevilacqua et al., 1989; Hennessy et al., 1991; Hirayama et
al., 1991; Royds et al., 1993; Stahl et al., 1991; Tokunaga et
al., 1993), although this was not the case in a study by Sastre-
Garau et al. (1992). Mutations and deletions of the nm23
gene have been shown in a number of primary tumours, such
as neuroblastomas, lung, breast and renal cancer (Leone et
al., 1991, 1993), but not in prostatic cancer (Brewster et al.,
1994). Taken together, these results suggest that the nm23
gene may have an important role in the mechanism of
metastasis in many solid tumour forms.
However, the role of the nm23-H 1 gene in tumour
progression and for metastatic potential of colorectal cancer,
is not clear. Conflicting observations have been reported on
the protein level (Ayhan et al., 1993; Haut et al., 1991;
Lacombe et al., 1991; Royds et al., 1994; Tannapfel et al.,
1995; Yamaguchi et al., 1993; Zeng et al., 1994); on the
mRNA level (Haut et al., 1991; Myeroff and Markowitz,
1993; Yamaguchi et al., 1993; Zeng et al., 1994); and on the
DNA-level (Bafico et al., 1993; Campo et al., 1994;
Cawkwell et al., 1994; Cohn et al., 1991; Heide et al.,
1994; lacopetta et al., 1994; Leone et al., 1991; Okada et al.,
1994; Steeg et al., 1991; Wang et al., 1993; Whitelaw and
Northover, 1994).
We have previously explored DNA ploidy, cell prolifera-
tive index (Lindmark et al., 1991) and p53 status (Kressner et
al., 1996) in colorectal cancer, without being able to detect
any substantial correlation to common clinicopathological
characteristics and to patient survival time. Nevertheless,
continued search for prognostic predictors in colorectal
cancer is essential. Thus far, no factors have been identified
capable of discriminating between patients truly cured by
surgery and patients having subclinical micrometastases in
Dukes' stages B and C (Dukes and Bussey, 1958). If such
factors were to be available, additional therapy could be
offered to selected patients running a high risk for tumour
relapse. Furthermore, selected patients could be included in
surveillance programmes.
The main goal in the present study was to evaluate
whether the expression of the nm23-HI protein, possibly
associated with events occurring later than p53-related events
in tumour progression (Fearon, 1994), was associated with
tumour stage and patient survival time in colorectal cancer.
In addition, we also investigated the relation between the
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Figure 1 Immunohistochemical anti-nm23-HI stainings of colorectal cancer illustrating (a) strong intensity, (b) moderate intensity
and (c) negative staining ( x 200 original magnification). (Arrows indicate positive tumour cells). A negative control, from which the
primary antibody was left out, is shown on the right in each case.
nm23-H1 expression and the other studied tumour character-
istics, as well as combinations thereof, in the prediction of
tumour stage and patient survival.
Materials and methods
Patients
Two-hundred and two potentially curable colorectal cancer
patients, with no preoperative indications of tumour spread
(120 colon, 82 rectum), were operated on between January
1987 and November 1990. None of the patients received
adjuvant chemotherapy; however, 28 patients with rectal
cancer obtained preoperative radiotherapy to 25 Gy in 5 days
(Glimelius et al., 1995). There were 117 women and 85 men;
mean age was 71 years (range 40-92 years). A total of 169
patients were potentially cured with a radically excised
tumour in Dukes' stages A-C. Thirty-three patients had
either non-radical surgery on distant metastases and were
designated Dukes' stage D. Survival was measured from the
time of resection until follow-up at the end of 1994. Median
survival time of 104 living patients was 66 months (range
50-93 months).
Tumour biopsies
Full-cross tumour sections, collected from 202 surgical
specimens, were frozen in dry-ice isopentane and stored at
-70°C. Serial cryosections were used for immunohistochem-
istry, and adjacent tumour tissue was used for flow cytometry
analysis. Biopsies for routine histopathology were taken from
all tumours.
Antibodies
Mouse monoclonal anti-nm23-H1 antibody, cloned NM301,
from Becton and Dickinson (San Jose, CA, USA), and mouse
monoclonal anti-p53 antibody, DO-7 (Dakopatts, Glostrup,Denmark) were used in concentrations of 1: 10 and 1: 500
respectively. Biotinylated horse anti-mouse IgG from Vector
Laboratories (Burlingame, CA, USA) was used in dilution
1: 200. Antibodies were omitted and replaced by mouse IgG
or dilution buffer, to test for specificity.
Immunohistochemical staining
Cryosections (6 ,um) were fixed in ice-cold acetone for
15 min. Incubation was performed for 60 min with the anti-
nm23-H1 antibody, which was diluted in phosphate-buffered
saline (PBS), supplemented by 0.1% bovine serum albumin
(BSA) and 5% normal horse serum for blocking of non-
specific staining. After repeated rinsing, endogenous perox-
idase was extinguished with 3% hydrogen peroxide in 100%
methanol for 15 min. Following incubation with biotinylated
horse anti-mouse secondary antibody for 30 min, staining
was performed with the avidin-biotin complex technique,
using Vectastatin ABC Elite kit from Vector Laboratories
with aminoethylcarbazole as peroxidase substrate. Finally,
the sections were counterstained with Mayer's haematoxylin.
Studies on DNA ploidy, cell proliferative index and p53
status are described in papers by Lindmark et al. (1991) and
Kressner et al. (1996).
Histopathological evaluation
Tumour stage and tumour differentiation Tumour differentia-
tion was assessed according to the WHO recommendations
(Morson and Sobin, 1976), and tumour staging according to
Dukes' classification system (Dukes and Bussey, 1958).
Staining patterns obtained using the anti-nm23-HJ antibody
The staining patterns were classified into four types: strong
homogeneous intensity, moderate homogeneous intensity,
Table I Nm23-H1 expression in colorectal cancer in different
Dukes' stages
Dukes' stage
A B C D Total
Strong homogeneous intensity 4 11 4 5 24
Moderate homogeneous intensity 11 25 11 7 54
Moderate focal intensity 12 29 11 12 64
Negative staining 8 28 15 9 60
Total 35 93 41 33 202
Table II The number and percentage of dead patients in Dukes'
stages B and C, in relation to tumour differentiation and nm23-H1
staining patterns
Poor
Dukes' stage differen-
B C B+C tiation
Dead/total no. Dead(%) No.
Strong homogeneous 2/11 2/4 4/15 27 0
intensity
Moderate homogeneous 4/25 7/11 11/36 31 3
intensity
Moderate focal intensity 8/29 4/11 12/40 30 2
Negative staining 8/28 11/15 19/43 44 9
Total 22/93 24/41 46/134 34 14
Table III Nm23-H1 expression in colorectal cancer with varied
tuomur differentiation
nm23-HJ Good Moderate Poor Total
Strong homogeneous intensity 5 17 2 24
Moderate homogeneous intensity 8 37 9 54
Moderate focal intensity 12 38 14 64
Negative staining 4 34 22 60
Total 29 126 47 202
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moderate focal intensity, or as negative (Figure 1). The
intraobserver variability was estimated in a second blind
evaluation.
Statistics The relation between nm23-H1 staining patterns
and the other studied tumour characteristics was determined
by x2 analysis, where P<0.05 was considered significant.
Survival curves were constructed using the life-table
(actuarial) method (Peto et al., 1977; Lawless, 1982).
Table IV Nm23-Hl expression in relation to DNA ploidy
nm23-HI ND AN Total
Strong homogeneous intensity 9 15 24
Moderate homogeneous intensity 25 29 54
Moderate focal intensity 27 37 64
Negative staining 38 22 60
Total 99 103 202
ND, near-diploid; AN, aneuploid (including tetraploid and
hyperploid tumours).
Table V Nm23-HI expression in relation to cell proliferative index
(SPF)
nm23-HI SPF (ND) SPF (AN)
Strong homogeneous intensity 12 (3-21) 13 (7-34)
Moderate homogeneous intensity 17 (10-27) 15 (6-37)
Moderate focal intensity 18 (6-35) 14 (7-27)
Negative staining 19 (9-39) 15 (8-24)
Total 17 (3-39) 14 (6-37)
Mean values with ranges given in parentheses (n=202). ND, near
diploid; AN, aneuploid (including tetraploid and hyperploid tumours).
Table VI Nm23-H1 expression in relation to p53 status (n = 178)
pS3- pS3-
nm23-Hl positive negative Total
Strong homogeneous intensity 13 10 23
Moderate homogeneous intensity 24 22 46
Moderate focal intensity 37 21 58
Negative staining 21 30 51
Total 95 83 178
100
co
.> 50-
C/)
n-
0 100 50
Months
Figure 2 Life-table plots showing the survival rates for patients
operated upon for colorectal cancer, with various anti-nm23-H1
staining patterns: 1, strong homogeneous intensity; 2, moderate
homogeneous intensity; 3, moderate focal intensity; and 4,
negative staining.
.~ ~ ~ I I. I.
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Results
nm23-HJ staining patterns
Positive staining was even in tumour cell cytoplasms, while
nuclei stained negatively (Figure 1). The intensity of the
cytoplasmic staining was either strong or moderate in virtually
all tumour cells in 24 and 54 sections respectively (Table I).
Sixty-four sections showed focally distributed moderate
staining intensity. Sixty sections stained entirely nm23-H1
negative. The intraobserver variability was low, with unequal
classification in 4 of 210 (2%) tumours. Tumour adjacent
normal bowel epithelium, present in 37 of 202 sections,
generally stained with strong homogeneous intensity.
nm23-HJ staining patterns - tumour stage and tumour
differentiation
No correlation was observed between the staining patterns
and tumour stage (Table I; x2=3.55; d.f. =9, P= 0.94 NS).
The number of patients who died in Dukes' stages B and C
did not vary significantly in relation to the nm23-HI staining
pattern (Table II; x2= 1.33, d.f. =3, P= 0.72, NS). Negative
tumours, and tumours showing moderate focal staining
intensity, were often poorly differentiated, more so than
tumours showing strong or moderate homogeneous staining
intensity (Table III; x2=6.02; d.f. =2, P<0.05).
nm23-HJ staining patterns - DNA ploidy and cellproliferative
index
Negative tumours were significantly more often near-diploid
than aneuploid (including tetraploid and hyperploid), as
compared with tumours showing any of the positive staining
patterns (Table IV, X2=6.84, d.f.= 1, P<0.01). The cell
proliferative index did not differ significantly in relation to
the various nm23-H1 staining patterns (Table V, X2=0.48,
d.f. =3, P=0.92 NS).
nm23-HJ staining patterns - p53 status
The distribution of p53-positive and -negative tumours did
not show any significant difference in relation to the nm23-
HI staining patterns in 178 of the 202 tumours in which both
stainings were available (Table VI, x2 = 5.70, d.f. =3,
P=0.12 NS).
nm23-HJ staining patterns - patient survival time
Patient survival curves showed no significant difference
according to the various nm23-H1 staining patterns (Figure
2). A similar observation was made when each of the studied
tumour characteristics was anlaysed in relation to nm23-H1
(data not shown).
Discussion
It was not possible to clarify in this report the possible
clinical significance of the differences observed in the nm23-
H1 staining patterns, as no correlation was found between
the nm23-H1 staining patterns and the other clinicopatholo-
gical tumour characteristics and patient survival time. Nor
was there any indication of a relation between nm23-H1
staining patterns and the formation of a basement membrane,
indirectly observed as tumour differentiation, or cell
proliferation, suggested by Howlett et al. (1994), Lombardi
et al. (1995) and Caligo et al. (1995).
These findings support observations made in some studies
showing that the nm23-H1 protein expression is independent
of the tumour stage in colorectal cancer (Haut et al., 1991;
Lacombe et al., 1991; Yamaguchi et al., 1993; Zeng et al.,
1994). Reduced expression was shown to be associated with
progressive tumour stage and distant metastasis in studies by
Ayhan et al. (1993) and Tannapfel et al. (1995). Moreover,
Yamaguchi et al. (1993) found that the expression of both
mRNA and protein was significantly lower in tumours
associated with liver metastasis than in those without such
metastasis. In a study by Royds et al. (1994), there was only
a marginal significance between the association of death from
colorectal cancer and the nm23 status.
Conflicting conclusions have been drawn in various
reports, based on the nm23-H1 expression on the mRNA
level. No correlation to the tumour stage was described by
Haut et al. (1991), Myeroff and Markowitz (1993), and Zeng
et al. (1994); Yamaguchi et al. (1993) presented a different
view in a study.
Allelic deletion and/or mutation of the nm23-H1 gene has,
in some papers, been shown to correlate with metastatic
progression in colorectal cancer, even if no correlation
between nm23-H1 protein and the initial tumour stage
could be observed (Campo et al., 1994; Cohn et al., 1991;
Wang et al., 1993). Steeg et al. (1991) claimed that colorectal
cancer provides an example where nm23 mRNA levels
remain constant, but allelic deletion is correlated with the
development of distant metastasis, and furthermore, that this
retained nm23 mRNA level may be explained by the fact that
the remaining allele compensates for the lost one. No changes
on the nm23-HI DNA level in primary colorectal cancer
(Bafico et al., 1993; Cawkwell et al., 1994; Whitelaw and
Northover, 1994), or in liver metatases (Heide et al., 1994),
have been shown by others. Okada et al. (1994) detected
allelic loss in only 3 of 29 (10%) informative colorectal
cancers and Iacopetta et al. (1994) in only 3 of 19 (16%).
Nm23-H1 allelic losses are considered as secondary events,
and specific nm23-H1 mutations have not been observed
frequently in colorectal cancer (Bafico et al., 1993. A late-
acting suppressor gene at or near the nm23-H1 locus has
been suggested (Cohn et al., 1991). It has been questioned
whether nm23 acts via the traditional recessive suppressor
gene model, and alterations, other than reduced nm23
expression, have been proposed as relevant to tumour
metastasis (Steeg et al., 1991).
Based on findings in this colorectal cancer study and on
the available literature, it may be concluded that there are
tissue-specific differences in the relative importance of the
nm23-H1 gene, and that the immunohistochemical expression
of nm23-H1 protein has been proven to be unrelated to
tumour progression and patient survival time. Thus, this
supports the opinon that the role of the nm23-HI genetic
alteration must be analysed in the context of association with
other genetic changes, rather than with the corresponding
protein expression.
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